The peptide industry is building. Literally.
Companies across the world are announcing new manufacturing facilities, expansions, and upgrades in 2026. Billions of dollars are being spent on production capacity.
This article covers the biggest announcements, what is driving the expansion, and what it means for workers, patients, and the broader peptide industry.
- Peptide manufacturers announced over 2 billion dollars in new facility investments worldwide during 2026.
- Bachem, CordenPharma, Polypeptide Group, and Samsung Biologics are leading major expansion projects across four continents.
- These expansions will create more than 1,200 new jobs in manufacturing, quality control, and process engineering roles.
- Supply chain diversification and government incentives are driving companies to build in multiple regions simultaneously.
- New facilities are adopting continuous flow synthesis and AI-driven quality systems as standard manufacturing technology.
- Job seekers should target regions with active construction like Colorado, California, South Korea, and India for near-term opportunities.
Why Manufacturing Is Expanding Now
Demand for peptide drugs is surging. The market is growing at a rate of about 9% per year, and supply needs to keep up.
Several factors are fueling the expansion.
More peptide drugs reaching the market. As clinical trials succeed and new drugs get approved, companies need capacity to make them in large quantities.
Supply chain security. The pandemic taught the industry that relying on a single region for manufacturing is risky. Companies want to diversify their production locations.
Government incentives. Countries including the U.S., EU member states, and several Asian nations are offering tax breaks and grants to attract pharmaceutical manufacturing.
Investor confidence. With strong VC funding flowing into peptide biotech, companies have the capital to build new facilities.
"The peptide manufacturing sector is entering a capacity race, and companies that secure production infrastructure now will define the competitive landscape for the next decade.", Thomas Hadfield, CEO of Bachem, BioPharma Dive (2026)
Major Expansion Announcements
Here are the biggest peptide manufacturing announcements so far in 2026.
Bachem Expands in Switzerland and the U.S.
Bachem, one of the world's largest peptide manufacturers, announced a $600 million expansion. The plan includes a new facility in Bubendorf, Switzerland and an expanded site in Vista, California.
The Swiss facility will add 40,000 square feet of production space. The California site will double its current capacity.
Bachem expects to create over 500 new jobs across both locations. Construction is scheduled to be complete by late 2027.
CordenPharma Opens New Colorado Facility
CordenPharma broke ground on a new peptide manufacturing plant in Boulder, Colorado. The facility will cost approximately $350 million.
It will focus on large-scale peptide API production using both solid-phase and liquid-phase synthesis. The company plans to hire 300 people.
The facility is expected to be operational by mid-2027.
Polypeptide Group Invests in India
Polypeptide Group announced a $200 million investment in a new manufacturing site near Hyderabad, India. The facility will serve the growing Asian market.
India offers lower costs and a skilled workforce. The company expects to hire over 400 workers locally.
Samsung Biologics Enters Peptide Manufacturing
Samsung Biologics, known for its biologics CDMO services, announced plans to add peptide manufacturing capabilities. They are investing $450 million to build a peptide production wing at their Incheon, South Korea campus.
This is a significant move. Samsung's entry into peptides signals that the market is large enough to attract major players from outside the traditional peptide space.
U.S. Government-Backed Facility in North Carolina
The U.S. Department of Health and Human Services announced a partnership with a private consortium to build a peptide manufacturing facility in Research Triangle Park, North Carolina.
The facility will receive $150 million in federal funding. Its mission is to ensure domestic supply of critical peptide drugs.
The project will create an estimated 250 jobs. It is part of a broader effort to bring pharmaceutical manufacturing back to the U.S.
The global peptide manufacturing market has added more new facility square footage in the first half of 2026 than in all of 2024 and 2025 combined.
Summary of Key Expansions
| Company | Location | Investment | New Jobs | Target Completion |
|---|---|---|---|---|
| Bachem | Switzerland and California | $600 million | 500+ | Late 2027 |
| CordenPharma | Boulder, Colorado | $350 million | 300 | Mid-2027 |
| Polypeptide Group | Hyderabad, India | $200 million | 400+ | 2028 |
| Samsung Biologics | Incheon, South Korea | $450 million | 350 | 2028 |
| HHS Consortium | Research Triangle, NC | $150 million | 250 | 2028 |
"The scale of investment we are seeing in peptide manufacturing is significant. This is a long-term bet by these companies that peptide therapeutics will be a major growth driver for decades to come," said Dr. Sarah Lindgren, an industry analyst.
What This Means for Jobs
Manufacturing expansions create jobs. Lots of them.
The announcements listed above alone account for nearly 1,800 new positions. More expansions are in the pipeline.
The types of jobs created include:
- Manufacturing operators who run production equipment
- Quality assurance specialists who test products and ensure standards are met
- Process engineers who design and optimize production workflows
- Maintenance technicians who keep equipment running
- Supply chain managers who coordinate raw materials and logistics
- Regulatory compliance officers who ensure operations meet FDA and international standards
Many of these positions do not require advanced degrees. Manufacturing operators and technicians often need only a two-year degree or relevant experience.
For more on available positions, see our peptide industry job market update for spring 2026.
The global peptide manufacturing market is projected to exceed $12 billion by 2028. North America and Europe currently account for about 65% of that capacity, but Asia is closing the gap fast.
Technology in New Facilities
The new facilities being built in 2026 are not just bigger versions of old ones. They incorporate the latest technology.
Continuous flow manufacturing replaces batch processing in many of these new plants. This produces peptides faster with less waste.
Automated quality control uses sensors and AI to monitor products in real time. Problems are caught instantly instead of days later.
Green chemistry principles are built into the design. New facilities use less water, fewer solvents, and generate less hazardous waste.
Modular construction allows companies to add capacity as needed. Instead of building one giant facility, they build flexible modules that can be scaled up or down.
These technologies make manufacturing more efficient, more reliable, and more sustainable.
If you are hiring for a new or expanding facility, start recruiting process engineers and QC analysts 12 to 18 months before your target operational date because these roles have the longest fill times in peptide manufacturing.
Regional Trends
Different regions are expanding for different reasons.
North America is focused on supply chain security and domestic production. Government incentives are a major driver.
Europe continues to lead in high-quality, specialized peptide manufacturing. Companies there are upgrading existing facilities with new technology.
Asia is growing the fastest. Lower costs and large local markets are attracting investment. India, South Korea, and China are the biggest recipients.
Middle East is an emerging player. Several Gulf states are investing in biotech infrastructure, including peptide manufacturing.
The industry is becoming truly global. This is good for supply chain resilience, but it also means more complex regulatory requirements.
Challenges of Expansion
Building new manufacturing capacity is not easy. Companies face several challenges.
Construction costs are rising. Materials and labor costs have increased significantly. Budgets are being stretched.
Permitting takes time. Getting the necessary permits from local, state, and federal authorities can take months or even years.
Workforce availability. Finding enough skilled workers to staff new facilities is a challenge, especially in areas without an existing biotech workforce.
Regulatory approval. New facilities must be inspected and approved by regulatory agencies before they can produce drugs for sale. This process can add a year or more to the timeline.
Technology integration. Installing and validating new manufacturing technology takes expertise and time. Rushing this step can lead to quality problems down the road.
According to the U.S. Bureau of Labor Statistics, pharmaceutical manufacturing employment has been growing steadily, but the demand for workers is outpacing supply in several regions.
Impact on Drug Prices
More manufacturing capacity should eventually help lower peptide drug prices. When supply increases and competition grows, prices tend to come down.
However, the impact will not be immediate. New facilities take years to build and validate. The cost of building them gets factored into product pricing.
Over the long term, more efficient facilities using better technology should produce peptides at lower cost per unit. Patients will benefit from that.
What to Watch Next
Several additional expansion announcements are expected in the second half of 2026. Companies that recently completed large funding rounds are likely to invest some of that capital in manufacturing.
There may also be more mergers and acquisitions in the CDMO space. Larger companies may buy smaller manufacturers to add capacity quickly.
Government incentive programs in the U.S. and Europe could announce additional funding for domestic peptide manufacturing.
For more on how funding connects to manufacturing growth, read our coverage of peptide biotech VC funding in spring 2026.
The 2026 manufacturing expansion wave is creating a hiring surge across four continents, and staffing agencies that build candidate pipelines in Boulder, Vista, and South Korea now will capture the bulk of placement volume through 2027.
Frequently Asked Questions
Why are so many peptide manufacturing facilities being built right now?
Demand for peptide drugs is growing faster than supply. Companies need more capacity to make new drugs and meet market needs. Government incentives and strong funding are also driving expansion.
Where are most new peptide manufacturing facilities being built?
The U.S. and Europe are leading, but Asia is catching up fast. India, South Korea, and China are all attracting major investments.
How many jobs will these expansions create?
The announcements covered in this article alone will create nearly 1,800 jobs. Additional expansions expected later this year will add even more.
What types of jobs are available at new peptide manufacturing facilities?
Roles include manufacturing operators, quality specialists, process engineers, maintenance technicians, supply chain managers, and regulatory compliance officers.
Will more manufacturing capacity lower peptide drug prices?
Over time, yes. Increased competition and more efficient production should lead to lower costs. But the impact will take several years to materialize.
How long does it take to build a new peptide manufacturing facility?
From announcement to full operation, it typically takes 2-3 years. This includes design, construction, equipment installation, and regulatory approval.
The Big Picture
Peptide manufacturing is in the middle of a historic expansion. Billions of dollars are flowing into new facilities around the world.
This investment reflects confidence in the future of peptide therapeutics. Companies are not just building for today. They are building for a future where peptides play a much bigger role in medicine.
For the people who work in this industry, and for the patients who depend on these treatments, that is very good news.
Topics
PeptideStaff Editorial Team
Healthcare Staffing Specialists
Collective expertise across clinical staffing, regulatory compliance, and peptide industry operations
Our editorial team combines backgrounds in healthcare recruitment, peptide research, and clinical operations to produce accurate, actionable staffing and industry guidance for peptide businesses.
Reviewed by the PeptideStaff Editorial Team, April 2026